Topics

International Stem Cell (ISCO) - Q119 results

11:56 EDT 5 Jun 2019 | Edison Investment Research

Edison Investment Research - Pharmaceuticals & healthcare - International Stem Cell : International Stem Cell (ISCO) reported Q119 revenues of $2.2m, down 15.8% compared with Q118 as both the biomedical and cosmetic businesses exhibited weakness. Biomedical revenues, which had been up 78.4% in 2018, were down 16.2% for the quarter. The profitability of the biomedical business also declined as revenues fell but expenses grew. The segment provided $0.8m in profits in Q118, but only $0.3m this quarter.
ISIN: US4603782016

Original Article: International Stem Cell (ISCO) - Q119 results

NEXT ARTICLE

More From BioPortfolio on "International Stem Cell (ISCO) - Q119 results"

Quick Search

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...